393 related articles for article (PubMed ID: 29993291)
1. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
Sun S; Du G; Xue J; Ma J; Ge M; Wang H; Tian J
Int J Immunopathol Pharmacol; 2018; 32():2058738418787991. PubMed ID: 29993291
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
3. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.
Miyazaki T; Moritake K; Yamada K; Hara N; Osago H; Shibata T; Akiyama Y; Tsuchiya M
J Neurosurg; 2009 Aug; 111(2):230-7. PubMed ID: 19199463
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
6. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Wainwright DA; Chang AL; Dey M; Balyasnikova IV; Kim CK; Tobias A; Cheng Y; Kim JW; Qiao J; Zhang L; Han Y; Lesniak MS
Clin Cancer Res; 2014 Oct; 20(20):5290-301. PubMed ID: 24691018
[TBL] [Abstract][Full Text] [Related]
7. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.
Lin SY; Yeh TK; Song JS; Hung MS; Cheng MF; Liao FY; Li AS; Cheng SY; Lin LM; Chiu CH; Wu MH; Lin YJ; Hsiao W; Sun M; Wang YH; Huang CH; Tang YC; Chang HH; Huang ZT; Chao YS; Shih C; Pan SL; Wu SY; Kuo CC; Ueng SH
Bioorg Chem; 2018 Apr; 77():600-607. PubMed ID: 29494816
[TBL] [Abstract][Full Text] [Related]
8. Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas.
Mitsuka K; Kawataki T; Satoh E; Asahara T; Horikoshi T; Kinouchi H
Neurosurgery; 2013 Jun; 72(6):1031-8; discussion 1038-9. PubMed ID: 23426156
[TBL] [Abstract][Full Text] [Related]
9. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
Wainwright DA; Balyasnikova IV; Chang AL; Ahmed AU; Moon KS; Auffinger B; Tobias AL; Han Y; Lesniak MS
Clin Cancer Res; 2012 Nov; 18(22):6110-21. PubMed ID: 22932670
[TBL] [Abstract][Full Text] [Related]
10. PCC0208009, an indirect IDO1 inhibitor, alleviates neuropathic pain and co-morbidities by regulating synaptic plasticity of ACC and amygdala.
Wang Y; Li CM; Han R; Wang ZZ; Gao YL; Zhu XY; Yu X; Du GY; Wang HB; Tian JW; Fu FH
Biochem Pharmacol; 2020 Jul; 177():113926. PubMed ID: 32217098
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
Yentz S; Smith D
BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
[TBL] [Abstract][Full Text] [Related]
12. Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review.
Wells G; Kennedy PT; Dahal LN
Front Immunol; 2021; 12():651687. PubMed ID: 33777052
[No Abstract] [Full Text] [Related]
13. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
14. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Zhang X; Ni Q; Wang Y; Fan H; Li Y
Biol Pharm Bull; 2018 Aug; 41(8):1194-1202. PubMed ID: 29848900
[TBL] [Abstract][Full Text] [Related]
16. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
Inaba T; Ino K; Kajiyama H; Yamamoto E; Shibata K; Nawa A; Nagasaka T; Akimoto H; Takikawa O; Kikkawa F
Gynecol Oncol; 2009 Nov; 115(2):185-92. PubMed ID: 19665763
[TBL] [Abstract][Full Text] [Related]
17. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
18. Feiji Recipe inhibits the growth of lung cancer by modulating T-cell immunity through indoleamine-2,3-dioxygenase pathway in an orthotopic implantation model.
Luo B; Que ZJ; Zhou ZY; Wang Q; Dong CS; Jiang Y; Hu B; Shi H; Jin Y; Liu JW; Li HG; Wang L; Tian JH
J Integr Med; 2018 Jul; 16(4):283-289. PubMed ID: 29752140
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
20. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
